Responsiveness of efficacy endpoints in clinical trials with over the counter analgesics for headache

Cephalalgia

Volumn 32, Issue 13, 2012, Pages 953-962

  Aicher, Bernhard ^a   Peil, Hubertus ^a   Peil, Barbara ^b   Diener, Hans Christoph ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

clinical relevance; headache; over the counter analgesics; randomized clinical trials; Responsiveness of efficacy endpoints; ROC curve calculations

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANALGESICS; DOUBLE-BLIND METHOD; HEADACHE; HUMANS; MULTICENTER STUDIES AS TOPIC; NONPRESCRIPTION DRUGS; PAIN MEASUREMENT; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROC CURVE;

EID: 84867004685     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412452047     Document Type: Article

References (44)

1. Wallenstein SL, Houde RW Methods in narcotics research. Ehrenpreis S Neidle A, ed. New York: Marcel Dekker ; 1975: 127-145.
2. Lipton RB. Methodologic issues in acute migraine clinical trials. Neurology. 2000 ; 55: 53-97
3. Huskisson EC. Measurement of pain. Lancet. 1974 ; 2: 1127-1131
4. Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: patient preference does not confound pain measurement. Pain. 1981 ; 10: 241-248
5. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986 ; 27: 117-126
6. Skovlund E, Flaten O. Response measures in the acute treatment of migraine. Cephalalgia. 1995 ; 15: 519-522
7. Goadsby PJ. The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci. 1999 ; 26 (Suppl. 3). S20 - S26
8. Salonen R. Drug comparisons: why are they so difficult?. Cephalalgia. 2000 ; 20 (Suppl. 2). 25-32
9. Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician's view. Cephalalgia. 2000 ; 20 (Suppl. 2). 14-24
10. McCrory DC, Gray RN, Tfelt-Hansen P, Steiner TJ, Taylor FR. Methodological issues in systematic reviews of headache trials: adapting historical diagnostic classifications and outcome measures to present-day standards. Headache. 2005 ; 45: 459-465
11. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991 ; 31: 295-299
12. Pilgrim AJ. Early-phase clinical trials in migraine: efficacy, safety and dose-finding. Cephalalgia. 1995 ; ((Suppl. 15)). 10-13
13. Pilgrim AJ Headache treatment: trial methodology and new drugs. Olesen J Tfelt-Hansen P, ed. Philadelphia: Lippincott-Raven Publishers ; 1997: 119-124.
14. Guidelines for controlled trials of drugs in migraine (first edition). Cephalalgia. 1991 ; 11: 1-12
15. Tfelt-Hansen P Headache treatment: trial methodology and new drugs. Olesen J Tfelt-Hansen P, ed. Philadelphia: Lippincott-Raven Publishers ; 1997: 157-160.
16. Pietrini U, De Luca M, Del Bene E. Endpoints to evaluate efficacy of symptomatic drugs in migraine: what do patients want?. Headache. 2002 ; 42: 948-949
17. Coeytaux RR, Frasier PY, Reid A. Patient-centered outcomes for frequent headaches. Headache. 2007 ; 47: 480-485
18. Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache. 2005 ; 45: 346-349
19. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 ; 47: 475-479
20. Friedman LM, Furberg CD, DeMets DL Fundamentals of clinical trials. Boston: John Wright PSG Inc ; 1982: 1-224.
21. Kirshner B, Guyatt GH. A methodological framework for assessing health indices. J Chron Dis. 1985 ; 38: 27-36
22. Pageler L, Diener HC, Pfaffenrath V, Peil H, Aicher B. Clinical relevance of efficacy endpoints in OTC headache trials. Headache. 2009 ; 49: 646-654
23. Bronfort G, Bouter LM. Responsiveness of general health status in chronic low back pain: a comparison of the COOP Charts and the SF-36. Pain. 1999 ; 83: 201-209
24. Beurskens AJHM, de Vet HCW, Köke AJA. Responsiveness of functional status in low back pain: a comparison of different instruments. Pain. 1996 ; 65: 71-76
25. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chron Dis. 1986 ; 39: 897-906
26. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000 ; 88: 287-294
27. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials?. Arthritis Rheum. 1995 ; 38: 1568-1580
28. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 ; 94: 149-158
29. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single dose, placebo-controlled parallel group study. Cephalalgia. 2005 ; 25: 776-787
30. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1998 ; 8 (Suppl. 7). 1-96
31. Pepe MS The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press ; 2003 :
32. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006 ; 4: 70-74
33. Statistical principles for clinical trials. CPMP/ICH/363/96. 1998 ;: 1-37
34. Lipton RB. Methodologic issues in acute migraine clinical trials. Neurology. 2000 ; 55 (Suppl. 2). S3 - S7
35. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006 ; 4: 79-79
36. Lipton RB, Stewart WF. Migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache. 1999 ; 39 (Suppl. 2). S20 - S26
37. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001 ; 23: 127-145
38. Dodick D. Patient perceptions and treatment preferences in migraine management. CNS Drugs. 2002 ; 16 (Suppl. 1). 19-24
39. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment?. Headache. 2002 ; 42 (Suppl. 1). 3-9
40. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000 ; 20: 765-786
41. Ramadan NM. Assessing the efficacy of drugs for the acute treatment of migraine: issues in clinical trial design. CNS Drugs. 2002 ; 16: 181-196
42. Antonaci F, Sances G, Guaschino E, De Cillis I, Bono G, Nappi G. Meeting patient expectations in migraine treatment: what are the key endpoints?. J Headache Pain. 2008 ; 9: 207-213
43. Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, et al. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia. 2010 ; 30: 1-16
44. Tfelt-Hansen P, McCaroll K, Lines C. Sum of pain intensity differences (SPID) in migraine trials. A comment based on four rizatriptan trials. Cephalalgia. 2002 ; 22: 664-666